Pharmacoepigenetics of Major Depression

Gabriel R. Fries; Harris A. Eyre; Chad Bousman; Joao Quevedo; Bernhard T. Baune

doi:10.1016/B978-0-12-813939-4.00027-9

Pharmacoepigenetics of Major Depression

Gabriel R. Fries, Harris A. Eyre, Chad Bousman, Joao Quevedo, Bernhard T. Baune

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Major depressive disorder is a leading cause of disability worldwide, and evidence suggests a strong genetic basis for its pathophysiology and treatment. Around 50% of patients do not achieve symptom remission following an initial antidepressant treatment, and there are no validated biomarkers of treatment response routinely used in clinics. While numerous pharmacogenetic tools have been developed to assist clinicians in the task of choosing the ideal antidepressant(s) for a given patient, emerging evidence suggests a key role for epigenetic markers, such as DNA methylation, in the prediction of antidepressant response. In this chapter we discuss recent clinical and preclinical findings of an association between epigenetic mechanisms and response to antidepressant treatment, as well as current limitations and future directions for the field of pharmacoepigenetics of depression.

Original language	English (US)
Title of host publication	Pharmacoepigenetics
Publisher	Elsevier
Pages	747-754
Number of pages	8
ISBN (Electronic)	9780128139394
DOIs	https://doi.org/10.1016/B978-0-12-813939-4.00027-9
State	Published - Jan 1 2019

Keywords

Antidepressants
Depression
DNA methylation
Histones
Pharmacoepigenetics

ASJC Scopus subject areas

Medicine(all)
Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.1016/B978-0-12-813939-4.00027-9

Cite this

@inbook{5efd9f3593c44cc88ff1ee4d95fd8fff,

title = "Pharmacoepigenetics of Major Depression",

abstract = "Major depressive disorder is a leading cause of disability worldwide, and evidence suggests a strong genetic basis for its pathophysiology and treatment. Around 50% of patients do not achieve symptom remission following an initial antidepressant treatment, and there are no validated biomarkers of treatment response routinely used in clinics. While numerous pharmacogenetic tools have been developed to assist clinicians in the task of choosing the ideal antidepressant(s) for a given patient, emerging evidence suggests a key role for epigenetic markers, such as DNA methylation, in the prediction of antidepressant response. In this chapter we discuss recent clinical and preclinical findings of an association between epigenetic mechanisms and response to antidepressant treatment, as well as current limitations and future directions for the field of pharmacoepigenetics of depression.",

keywords = "Antidepressants, Depression, DNA methylation, Histones, Pharmacoepigenetics",

author = "Fries, {Gabriel R.} and Eyre, {Harris A.} and Chad Bousman and Joao Quevedo and Baune, {Bernhard T.}",

year = "2019",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-813939-4.00027-9",

language = "English (US)",

pages = "747--754",

booktitle = "Pharmacoepigenetics",

publisher = "Elsevier",

address = "United States",

}

TY - CHAP

T1 - Pharmacoepigenetics of Major Depression

AU - Fries, Gabriel R.

AU - Eyre, Harris A.

AU - Bousman, Chad

AU - Quevedo, Joao

AU - Baune, Bernhard T.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Major depressive disorder is a leading cause of disability worldwide, and evidence suggests a strong genetic basis for its pathophysiology and treatment. Around 50% of patients do not achieve symptom remission following an initial antidepressant treatment, and there are no validated biomarkers of treatment response routinely used in clinics. While numerous pharmacogenetic tools have been developed to assist clinicians in the task of choosing the ideal antidepressant(s) for a given patient, emerging evidence suggests a key role for epigenetic markers, such as DNA methylation, in the prediction of antidepressant response. In this chapter we discuss recent clinical and preclinical findings of an association between epigenetic mechanisms and response to antidepressant treatment, as well as current limitations and future directions for the field of pharmacoepigenetics of depression.

AB - Major depressive disorder is a leading cause of disability worldwide, and evidence suggests a strong genetic basis for its pathophysiology and treatment. Around 50% of patients do not achieve symptom remission following an initial antidepressant treatment, and there are no validated biomarkers of treatment response routinely used in clinics. While numerous pharmacogenetic tools have been developed to assist clinicians in the task of choosing the ideal antidepressant(s) for a given patient, emerging evidence suggests a key role for epigenetic markers, such as DNA methylation, in the prediction of antidepressant response. In this chapter we discuss recent clinical and preclinical findings of an association between epigenetic mechanisms and response to antidepressant treatment, as well as current limitations and future directions for the field of pharmacoepigenetics of depression.

KW - Antidepressants

KW - Depression

KW - DNA methylation

KW - Histones

KW - Pharmacoepigenetics

UR - http://www.scopus.com/inward/record.url?scp=85123659679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123659679&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-813939-4.00027-9

DO - 10.1016/B978-0-12-813939-4.00027-9

M3 - Chapter

AN - SCOPUS:85123659679

SP - 747

EP - 754

BT - Pharmacoepigenetics

PB - Elsevier

ER -

Pharmacoepigenetics of Major Depression

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this